Certain diabetes drugs may be linked to increased risk of inflammatory bowel disease

March 21, 2018, British Medical Journal

Use of certain diabetes drugs, known as dipeptidyl peptidase-4 inhibitors, is associated with an increased risk of inflammatory bowel disease, the digestive condition that causes stomach pain and bloating, finds a study published by The BMJ today.

The researchers stress that the absolute risk is low - and that their findings need to be replicated - but say "physicians should be made aware of this possible association."

Dipeptidyl peptidase-4 (DPP-4) inhibitors are a relatively new type of diabetes drug that lower levels. They are usually prescribed for people with type 2 diabetes who have not responded well to other drugs.

They work by blocking the DPP-4 enzyme that is involved in the body's inflammatory response and regulates gut hormones. Some data suggest that lower serum levels of DPP-4 enzyme may be linked to increased in patients with , but no study has investigated the impact of inhibiting this enzyme on the occurrence of this disease.

So a Canadian team, led by Laurent Azoulay at McGill University, set out to assess whether the use of DPP-4 inhibitors is associated with inflammatory bowel disease in patients with type 2 diabetes.

They analysed data from the UK's Clinical Practice Research Database for 141,170 patients aged at least 18 years of age, who were starting antidiabetic drugs between 2007 and 2016.

Patients initially treated with insulin and those with a history of inflammatory bowel disease or similar conditions were excluded. Factors such as age, weight (BMI), smoking status, alcohol related disorders and complications of diabetes were taken into account.

Participants were monitored for an average of three and a half years, during which time 208 new cases of inflammatory bowel disease were recorded (an incidence rate of 37.7 per 100,000 person years).

Overall, use of DPP-4 inhibitors was associated with a 75% increased risk of inflammatory bowel disease (53.4 cases per 100,000 person years) compared with use of other antidiabetic drugs (34.5 cases per 100,000 person years).

This association gradually increased with longer durations of DPP-4 inhibitor use, reaching a peak after three to four years and decreasing after more than four years of use.

Although no single DPP-4 inhibitor was statistically associated with inflammatory bowel disease, these findings remained unchanged after further analyses to test the strength of the results.

This is an observational study, so no firm conclusions can be drawn about cause and effect, and the researchers point to some limitations, such as possible misclassification of drugs or cases. And while they adjusted for several risk factors, they cannot rule out the possibility that other unmeasured (confounding) factors may have influenced the results.

Nevertheless, they say in this first population based study, the use of dipeptidyl peptidase-4 inhibitors was associated with an increased risk of inflammatory bowel disease.

"Although our findings need to be replicated, physicians should be aware of this possible association and perhaps refrain from prescribing DPP-4 inhibitors for people at high risk, such as those with a family history of disease or with known autoimmune conditions," they conclude.

Explore further: Inflammatory bowel disease in childhood associated with increased risk of cancer

More information: Dipeptidyl peptidase-4 inhibitors and incidence of inflammatory bowel disease among patients with type 2 diabetes: population based cohort study, BMJ (2018). www.bmj.com/content/360/bmj.k872

Related Stories

Inflammatory bowel disease in childhood associated with increased risk of cancer

September 21, 2017
Children who develop inflammatory bowel disease (ulcerative colitis or Crohn's disease) run a higher risk of cancer, both in childhood and later in life, a study from Karolinska Institutet published in the BMJ reports.

Calcium supplements may boost risk of abnormal bowel growths

March 2, 2018
Calcium supplements, taken with or without vitamin D, may increase the risk of small growths in the large bowel (colon) called polyps, suggest results from a large US trial published online in the journal Gut.

Older people with bowel disease receive older medicines

November 13, 2017
Inflammatory bowel disease is common amongst older people and there are big differences in the choice of treatment for different age groups. Patients over the age of 60 often receive cortisone drugs instead of more modern ...

Researchers uncover link between heart attacks and inflammatory bowel disease

March 6, 2018
University Hospitals Harrington Heart & Vascular Institute researchers Muhammad Panhwar, MD, and Mahazarin Ginwalla, MD, recently concluded a study of more than 22 million patients that suggests a strong connection between ...

Inflammatory bowel disease increases likelihood of a heart attack

March 1, 2018
An analysis of medical-record data from more than 17.5 million patients found that people with inflammatory bowel disease (IBD) are at elevated risk for a heart attack, regardless of whether or not they have traditional risk ...

Weight loss surgery linked to an increased risk of inflammatory bowel disease

March 7, 2018
A new Alimentary Pharmacology & Therapeutics analysis has found a link between the development of inflammatory bowel disease (IBD) and a past history of weight loss surgery.

Recommended for you

Inflammation can lead to circadian sleep disorders

October 31, 2018
Inflammation, which is the root cause of autoimmune disorders including arthritis, Type 1 diabetes, irritable bowel syndrome and Crohn's disease, has unexpected effects on body clock function and can lead to sleep and shiftwork-type ...

Machine learning tool predicts the potential of peptides as immune activators

October 23, 2018
The immune system keeps T cells under control by regulating precisely when they can respond to a pathogen. For instance, helper T cells only turn "on" if other immune cells, such as antigen-presenting cells (APCs) present ...

A new mechanism in the control of inflammation

October 18, 2018
After infection or tissue injury, the inflammatory immune response attacks the infection and repairs the damaged tissue. However, sometimes excess inflammation can have the opposite effect, increasing injury in a process ...

Sugar, a 'sweet' tool to understand brain injuries

October 15, 2018
Australian researchers have developed ground-breaking new technology which could prove crucial in treating brain injuries and have multiple other applications, including testing the success of cancer therapies.

Scientists reveal new cystic fibrosis treatments work best in inflamed airways

October 11, 2018
A new UNC School of Medicine study shows that two cystic fibrosis (CF) drugs aimed at correcting the defected CFTR protein seem to be more effective when a patient's airway is inflamed. This is the first study to evaluate ...

Microbiome profiling reveals associations with ulcerative colitis severity, treatment

October 11, 2018
A study of gut microbes from more than 400 children points to how the microbiome behaves in this inflammatory bowel disease.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.